{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-001260","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.833206+00:00","generated_at":"2026-05-24T06:48:00.717193+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Onconetix presents Proclarix data at EAU; 96% sensitivity, 22% biopsy avoidance in Danish cohort","bullets":["Proclarix evaluated in 808 patients; in targeted subpopulation (n=371), negative test gave 5% csPCa probability vs 14% for %fPSA (p=0.028).","Proclarix avoided 22% of biopsies while missing only 3 of 101 csPCa cases (2 GG2, 1 GG3).","In extended population (n=654, PSA 2-20 ng/mL), sensitivity 96%, specificity significantly higher than %fPSA and ERSPC RC (p<0.001).","Data presented March 23, 2025 at EAU congress in Madrid; study led by Ahmed H. Zedan, MD, PhD of Lillebaelt Hospital."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-001260","json":"https://secwatch.observer/filing/0001013762-25-001260.json","markdown":"https://secwatch.observer/filing/0001013762-25-001260.md","text":"https://secwatch.observer/filing/0001013762-25-001260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000101376225001260/0001013762-25-001260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000101376225001260/ea0235277-8k_oncon.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:48:00.717193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}